RxDoctor Payments Data

Renata Ratajczak Dambek, MD

Internal Medicine · Malabar, FLNPI 1679589378

Payments from drug & device makers

$1,143in general payments, 2019–2025

Across 62 payments — averaging $18.43 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$356
  • Novo Nordisk$150
  • Astellas Pharma US Inc$142
  • AstraZeneca$131
  • Amarin Pharma, Inc.$70
  • Amgen$58
  • plus $237 from 9 others

What the payments were for

  • Food & beverage$1,04491%
  • Education$999%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$1,143 in reported general payments places this provider in the 70th percentile of 8,530 internal medicine providers in Florida.

See all internal medicine providers in Florida

Medicare billing

Part B allowed, 2024
$113,469
Medicare patients
359
Services billed
1,232

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide66$88,963
EliquisApixaban35$48,549
MounjaroTirzepatide18$30,148
XareltoRivaroxaban32$29,901
JardianceEmpagliflozin23$16,861
MyrbetriqMirabegron25$15,717
JanuviaSitagliptin Phosphate12$12,782
Breo ElliptaFluticasone/Vilanterol20$11,422
TradjentaLinagliptin14$10,901
Levothyroxine Sodium378$6,474
Novolog Mix 70-30 FlexpenInsulin Aspart Prot/Insuln Asp23$6,246
Doxepin Hcl11$4,026
Atorvastatin Calcium241$3,882
Metoprolol Succinate167$3,664
Losartan Potassium196$3,572

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic$150$88,96366 claims
PfizerEliquis$16$48,54935 claims
Lilly USA, LLCMounjaro$13$30,14818 claims
Johnson & JohnsonXarelto$34$29,90132 claims
Boehringer IngelheimJardiance, Tradjenta$49$27,76237 claims
Astellas Pharma US IncMyrbetriq$142$15,71725 claims
MerckJanuvia$25$12,78212 claims
AbbVieSynthroid$356$3,34845 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 8,530 internal medicine providers in Florida.

Other internal medicine in Malabar

See the full list for Florida

Where these figures come from

Is this you, or does something look wrong? →